Keywords: lundbeck, eps, up, shares, fall, ceo, exit
Lundbeck's EPS up 65%; shares fall on CEO exit
Article | 17 March 2008
Full-year 2007 operating profit at Danish drugmaker H Lundbeck, including non-recurring items, was 2.69 billion Danish kroner ($556.3 million), up 51%, while earnings per ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
